1 active not recruiting, 1 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Withdrawn 1 |
Follow Selective Estrogen Receptor Modulators: new trials by email Literature Review of Selective Estrogen Receptor Modulators trials Research Report on Selective Estrogen Receptor Modulators
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI - Breast Cancer, ER-positive Breast Cancer | Phase 2 | Active not recruiting | University of Miami | 24 | 2023-06-12 | 2026-01-13 |
| Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer Sabizabulin, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator - Metastatic Breast Cancer | Phase 2 | Withdrawn | Veru Inc. | 2023-03-15 | 2023-03-24 |
Breast Neoplasms (2)
University of Miami (1) · Veru Inc. (1)
United States (2)